Hauser et al. managing relapse advancement in RMS, ocrelizumab (OCR) also demonstrated medical benefits in individuals with PPMS and became the 1st approved drug because of this disease program. With this review, we offer a synopsis of the existing anti-CD20 mabs utilized or examined for the treating ZL0420 MSnamely rituximab […]
Daily Archives: June 24, 2025
1 post